Resmetirom, Survodutide, and Tirzepatide Doses Significantly Improve Liver Fibrosis and Achieve NASH Resolution in MASLD F1-F3 Patients
Background
Metabolism-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally, often progressing to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, and cirrhosis. Despite its widespread impact, effective pharmacological therapies specifically tailored for MASLD patients with moderate fibrosis (F1-F3 stages) remain limited. Existing meta-analyses have often lacked specific drug dosages, hindering precise clinical application. This study addresses this gap by evaluating the efficacy of various pharmacotherapies at defined dosages in improving liver fibrosis within this specific patient population.
Study Design
This network meta-analysis identified 13 randomized controlled trials (RCTs) involving 3,871 adult patients with MASLD and fibrosis stages F1-F3. Researchers analyzed 12 pharmacological interventions aimed at improving liver fibrosis. Data was sourced from three major databases, with identification up to July 21, 2025. The primary endpoint assessed was the achievement of NASH resolution without worsening of fibrosis, comparing active interventions against a placebo control arm.
Results
Compared to placebo, 6 active pharmacological interventions demonstrated significant efficacy in achieving NASH resolution without worsening of fibrosis. These included resmetirom 80 mg/day (RR = 2.56, 95%CI: 1.09, 6.02), resmetirom 100 mg/day (RR = 3.07, 95%CI: 1.31, 7.16), survodutide 6 mg/week (RR = 7.25, 95%CI: 2.07, 25.36), tirzepatide 5 mg/week (RR = 4.29, 95%CI: 1.33, 13.82), tirzepatide 10 mg/week (RR = 5.31, 95%CI: 1.67, 16.85), and tirzepatide 15 mg/week (RR = 6.00, 95%CI: 1.91, 18.89). In direct comparisons, denifanstat 50 mg/day (RR = 2.46, 95%CI: 1.18, 5.13) also showed significant improvement over placebo, alongside the aforementioned doses of resmetirom, survodutide, and tirzepatide. Notably, survodutide 6 mg/week demonstrated the highest relative risk for NASH resolution without fibrosis worsening. This comprehensive analysis provides specific dosage-dependent efficacy data for these promising therapies.
Survodutide 6 mg/week showed the highest efficacy, increasing the likelihood of NASH resolution without fibrosis worsening by 7.25-fold compared to placebo (95%CI: 2.07, 25.36).
Key Findings
- Resmetirom 80 mg/day improved NASH resolution without fibrosis worsening by 2.56-fold vs. placebo.
- Resmetirom 100 mg/day improved NASH resolution without fibrosis worsening by 3.07-fold vs. placebo.
- Survodutide 6 mg/week showed the highest efficacy, improving NASH resolution without fibrosis worsening by 7.25-fold vs. placebo.
- Tirzepatide 5 mg/week, 10 mg/week, and 15 mg/week significantly improved NASH resolution by 4.29-fold, 5.31-fold, and 6.00-fold respectively vs. placebo.
- Denifanstat 50 mg/day was 2.46-fold more effective than placebo in direct comparisons for fibrosis improvement.
Why It Matters
This network meta-analysis provides crucial, dosage-specific evidence for treating MASLD patients with F1-F3 fibrosis, a population with high unmet medical need. Clinicians and biohackers can now consider specific doses of resmetirom, survodutide, and tirzepatide as effective options for improving liver fibrosis and achieving NASH resolution. The explicit dosage information (resmetirom 80 mg/day, survodutide 6 mg/week, tirzepatide 5-15 mg/week) is highly protocol-relevant, enabling more informed treatment decisions. This moves us closer to personalized medicine for MASLD, highlighting the potential for these agents to prevent progression to more severe liver disease and associated complications. Further research is needed on long-term outcomes and potential combination strategies.
masld
nash
liver-fibrosis
resmetirom
survodutide
tirzepatide